Page last updated: 2024-11-05

thalidomide and Hereditary Autoinflammation Diseases

thalidomide has been researched along with Hereditary Autoinflammation Diseases in 1 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Research Excerpts

ExcerptRelevanceReference
" The efficacy and adverse events were evaluated and recorded every 3 months."1.91Efficacy and safety of thalidomide in children with monogenic autoinflammatory diseases: a single-center, real-world-evidence study. ( Gao, S; Gou, L; Li, J; Ma, M; Song, H; Wang, C; Wang, L; Wang, W; Yu, Z; Zhang, C; Zhong, L; Zhou, Y, 2023)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Zhang, C1
Yu, Z1
Gao, S1
Ma, M1
Gou, L1
Wang, C1
Wang, L1
Li, J1
Zhong, L1
Zhou, Y1
Wang, W1
Song, H1

Other Studies

1 other study available for thalidomide and Hereditary Autoinflammation Diseases

ArticleYear
Efficacy and safety of thalidomide in children with monogenic autoinflammatory diseases: a single-center, real-world-evidence study.
    Pediatric rheumatology online journal, 2023, Oct-17, Volume: 21, Issue:1

    Topics: Adenosine Deaminase; Child; Cryopyrin-Associated Periodic Syndromes; Familial Mediterranean Fever; H

2023